Printer Friendly

FzioMed Awarded New U.S. Patent For Oxiplex Biomaterial Technology.

SAN LUIS OBISPO, Calif. -- FzioMed, Inc. announced today that it has been awarded a new United States patent covering the company's Oxiplex(R) technology. Oxiplex is a versatile polymer biomaterial developed by FzioMed for use in a wide variety of surgical specialties.

The new patent, US 6,869,938, covers compositions of polyacids and polyethers, and methods for their use in reducing postsurgical adhesions.

"Our Oxiplex synthetic technology represents the next generation in biomaterials," said Richard Berg, Ph.D., Vice President of Research and Development for FzioMed, Inc. "We're pleased to receive another patent that deepens coverage for our pipeline of Oxiplex-based products."

FzioMed is a privately held medical company engaged in the development and commercialization of synthetic, absorbable biomaterials based on the company's patented Oxiplex technology. FzioMed is developing products for the prevention of postsurgical adhesions, tissue augmentation and regeneration, and the delivery of drugs. Oxiplex is an innovative polymer technology with potential uses across a wide variety of specialties including orthopedics, gynecology, general surgery, cardiac, neurosurgery and aesthetic surgery. FzioMed products include Oxiplex/SP Gel, the leading adhesion barrier for spine surgery, currently marketed outside of the United States. Other FzioMed products are in various stages of development and commercialization, and are directed towards high growth markets in the rapidly growing field of biosurgery materials.

FzioMed(R) and Oxiplex(R) are registered trademarks of FzioMed, Inc.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 11, 2005
Previous Article:Network Engines Schedules Webcast to Discuss Fiscal Second Quarter Results.
Next Article:Adjoined Consulting Celebrates Five Years of Impressive Growth; Clear Vision, a Successful Model and Solid Execution Contribute to 50% CAGR...

Related Articles
Researchers and foundrymen examine ways to promote CMMCs.
Bone fractures: treatment and risks.
Chin implant. (Product Marketplace).
FzioMed to Present at Rodman & Renshaw Techvest Global Healthcare Conference.
Implants for head, face.
FzioMed Granted Patent Expanding Oxiplex(R) Technology in Drug Delivery and Hemostasis.
FzioMed Receives NIH Grant to Study Injectable Delivery of Bone Growth Peptides for Spinal Fusion.
Comprehensive Review Published on FzioMed Technology for Postsurgical Adhesion Prevention.
FzioMed Granted Patent Expanding Biomaterial Technology in the Field of Aesthetic Medicine, Soft Tissue Augmentation.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters